Regression of Melanoma Nodules in a Patient Treated With Ranitidine

Thomas J Smith, Jeffrey W. Clark, Martin B. Popp

Research output: Contribution to journalArticle


Human malignant melanoma may regress spontaneously or with immunotherapy, such as Calmette-Guerin bacillus, interferon alfa, interleukin-2, and interleukin-2 plus lymphokine-activated killer cells. Histamine type 2 receptor antagonists can modulate immune function by inhibiting suppressor T-cell induction and activity, and melanoma regressions have been reported after the use of cimetidine with coumarin or interferon alfa. This article describes the complete regression of melanoma nodules in a patient treated with ranitidine hydrochloride, another histamine type 2—receptor antagonist. Ranitidine and cimetidine should be considered to be possibly active immunotherapeutic agents in the design and evaluation of clinical trials.

Original languageEnglish (US)
Pages (from-to)1815
Number of pages1
JournalArchives of Internal Medicine
Issue number10
Publication statusPublished - 1987
Externally publishedYes


ASJC Scopus subject areas

  • Internal Medicine

Cite this